This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Dong Ki Lee, PhD
Founder and CEO at OliX Pharmaceuticals
Speaker

Profile

Dong Ki Lee, Ph.D. is the Chief Executive Officer of OliX Pharmaceuticals, a biotechnology company developing next-generation RNAi therapeutics. He received his B.S. in Chemistry from KAIST and his Ph.D. in Molecular Biology from Cornell University, establishing a strong foundation in both chemistry and life sciences. He is also a Professor of Chemistry at Sungkyunkwan University, where he contributes to teaching and research. At OliX, he leads the development of the company’s proprietary asiRNA platform and oversees multiple therapeutic programs addressing significant unmet needs. His work focuses on advancing RNAi technologies toward clinical applications and translating innovative oligonucleotide platforms into impactful therapies.

Agenda Sessions

  • Advancing RNAi Therapeutics for Ocular Disorders

    2:30pm